Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Journal Article
PMID (11756186)
Authors Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG
Title FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
Journal Blood
Vol 99
Issue 1
Date 2002 Jan 1
URL
Abstract Text FLT3 receptor tyrosine kinase is expressed on lymphoid and myeloid progenitors in the hematopoietic system. Activating mutations in FLT3 have been identified in approximately 30% of patients with acute myelogenous leukemia, making it one of the most common mutations observed in this disease. Frequently, the mutation is an in-frame internal tandem duplication (ITD) in the juxtamembrane region that results in constitutive activation of FLT3, and confers interleukin-3 (IL-3)-independent growth to Ba/F3 and 32D cells. FLT3-ITD mutants were cloned from primary human leukemia samples and assayed for transformation of primary hematopoietic cells using a murine bone marrow transplantation assay. FLT3-ITDs induced an oligoclonal myeloproliferative disorder in mice, characterized by splenomegaly and leukocytosis. The myeloproliferative phenotype, which was associated with extramedullary hematopoiesis in the spleen and liver, was confirmed by histopathologic and flow cytometric analysis. The disease latency of 40 to 60 days with FLT3-ITDs contrasted with wild-type FLT3 and enhanced green fluorescent protein (EGFP) controls, which did not develop hematologic disease (> 200 days). These results demonstrate that FLT3-ITD mutant proteins are sufficient to induce a myeloproliferative disorder, but are insufficient to recapitulate the AML phenotype observed in humans. Additional mutations that impair hematopoietic differentiation may be required for the development of FLT3-ITD-associated acute myeloid leukemias. This model system should be useful to assess the contribution of additional cooperating mutations and to evaluate specific FLT3 inhibitors in vivo.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
FLT3 N676K FLT3 Inhibitor
FLT3 F612_G613insGYVDFREYEYDLKWEFRPRENLEF FLT3 Inhibitor
FLT3 V592G FLT3 Inhibitor
FLT3 D835X FLT3 Inhibitor
FLT3 R595_L601dup FLT3 Inhibitor
FLT3 D835A FLT3 Inhibitor
FLT3 D835N FLT3 Inhibitor
FLT3 Y599_D600insPAPQIMSTSTLISENMNIA FLT3 Inhibitor
FLT3 act mut FLT3 Inhibitor
FLT3 V579A FLT3 Inhibitor
FLT3 Y599_D600insGLYVDFREYEY FLT3 Inhibitor
FLT3 D835del FLT3 Inhibitor
FLT3 R834Q FLT3 Inhibitor
FLT3 F590_F605dup FLT3 Inhibitor
FLT3 Y842C FLT3 Inhibitor
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE FLT3 Inhibitor
FLT3 Y599_D600insEYEYEYEY FLT3 Inhibitor
FLT3 D835G FLT3 Inhibitor
FLT3 S840_N841insGS FLT3 Inhibitor
FLT3 F594C FLT3 Inhibitor
FLT3 F594_D600dup FLT3 Inhibitor
FLT3 D835V FLT3 Inhibitor
FLT3 F594L FLT3 Inhibitor
FLT3 S451F FLT3 Inhibitor
FLT3 D835Y FLT3 Inhibitor
FLT3 over exp FLT3 Inhibitor
FLT3 I867S FLT3 Inhibitor
FLT3 D839G FLT3 Inhibitor
FLT3 Y842H FLT3 Inhibitor
FLT3 L576R FLT3 Inhibitor
FLT3 S585_F594dup FLT3 Inhibitor
FLT3 N841I FLT3 Inhibitor
FLT3 Y572C FLT3 Inhibitor
FLT3 W603_E604insDREYEYDLKW FLT3 Inhibitor
FLT3 A680V FLT3 Inhibitor
FLT3 amp FLT3 Inhibitor
FLT3 I836del FLT3 Inhibitor
FLT3 Y597_K602dup FLT3 Inhibitor
FLT3 F594Y FLT3 Inhibitor
FLT3 D835E FLT3 Inhibitor
FLT3 Y599_D600insSTDNEYFYVDFREYEY FLT3 Inhibitor
FLT3 exon 14 ins FLT3 Inhibitor
FLT3 D835H FLT3 Inhibitor
FLT3 V592A FLT3 Inhibitor
FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL FLT3 Inhibitor
FLT3 D593_D600dup FLT3 Inhibitor
FLT3 E598_Y599insDVDFREYE FLT3 Inhibitor
FLT3 F590_Y591delinsGD FLT3 Inhibitor
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE insertion gain of function FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE results in the insertion of 22 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids E598 and Y599 (PMID: 11756186). E598_Y599insGLVQVTGSSDNEYFYVDFREYE confers a gain of function on Flt3 protein as indicated by transformation of cells in culture and induction of myeloproliferative disorder in mouse models (PMID: 11756186).
FLT3 F590_F605dup duplication gain of function FLT3 F590_F605dup indicates the insertion of 16 duplicate amino acids, phenylalanine (F)-590 through phenylalanine (F)-605, in the juxtamembrane region of the Flt3 protein (PMID: 11756186). F590_F605dup results in constitutive phosphorylation of Flt3, activation of Stat5 and Erk signaling, and transformation of cells in culture (PMID: 10698507).
FLT3 F590_Y591delinsGD indel gain of function FLT3 F590_Y591delinsGD results in a deletion of 2 amino acids in the juxtamembrane domain of the Flt3 protein from amino acids 590 to 591, combined with the insertion of a glycine (G) and an aspartic acid (D) at the same site (PMID: 11756186). F590_Y591delinsGD results in constitutive phosphorylation of Flt3, activation of Stat5 signaling, and transformation of cells in culture (PMID: 16410449).
FLT3 F612_G613insGYVDFREYEYDLKWEFRPRENLEF insertion gain of function - predicted FLT3 F612_G613insGYVDFREYEYDLKWEFRPRENLEF results in the insertion of 24 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids F612 and G613 (UniProt.org, PMID: 11756186). F612_F613insGYVDFREYEYDLKWEFRPRENLEF results in transformation of cultured cells (PMID: 11756186) and therefore, is predicted to lead to a gain of Flt3 protein function.
FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL insertion gain of function FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL results in the insertion of 28 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids L610 and E611 (UniProt.org, PMID: 11756186). L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL results in constitutive phosphorylation of Flt3, activation of Stat5 and Mapk signaling, and transformation of cultured cells (PMID: 10698507, PMID: 11756186).
FLT3 R595_L601dup duplication gain of function FLT3 R595_L601dup (also referred to as FLT3 L601_K602insREYEYDL) indicates the insertion of 7 duplicate amino acids, arginine (R)-595 through leucine(L)-601, in the juxtamembrane region of the Flt3 protein (PMID: 11756186). R595_L601dup results in constitutive phosphorylation of Flt3, activation of Stat5 and Erk signaling, transformation of cells in culture, and induction of myeloproliferative disorder in mouse models (PMID: 18068628, PMID: 11756186).
FLT3 Y599_D600insGLYVDFREYEY insertion gain of function - predicted FLT3 Y599_D600insGLYVDFREYEY results in the insertion of 11 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids 599 and 600 (PMID: 11756186). Y599_D600insGLYVDFREYEY results in transformation in cell culture (PMID: 11756186) and therefore, is predicted to lead to a gain of Flt3 protein function.
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References